Skip to main content

Advertisement

Table 1 Relationship between MMP13 and ETV4 transcripts levels and classical clinical biological parameters in 456 breast cancer samples

From: ETV4 transcription factor and MMP13 metalloprotease are interplaying actors of breast tumorigenesis

   Number of patients (%)
Total population (%) Low ETV4 High ETV4-Low MMP13 High ETV4-High MMP13 P valuea
Total 456 (100.0) 82 (18.0) 255 (55.9) 119 (26.1)  
Age, yr
  ≤ 50 98 (21.5) 10 (12.2) 60 (23.5) 28 (23.5) 0.075 (NS)
  > 50 358 (78.5) 72 (87.8) 195 (76.5) 91 (76.5)  
SBR histological gradeb, c
 I 58 (13.0) 10 (12.3) 37 (15.0) 11 (9.2) 0.24 (NS)
 II 229 (51.2) 48 (59.3) 122 (49.4) 59 (49.6)  
 III 160 (35.8) 23 (28.4) 88 (35.6) 49 (41.2)  
Lymph node statusd
 0 119 (26.1) 21 (25.9) 67 (26.5) 31 (26.3) 0.085 (NS)
 1–3 237 (52.1) 37 (45.7) 144 (56.9) 56 (47.5)  
  > 3 96 (21.8) 23 (28.4) 42 (16.6) 31 (26.3)  
Macroscopic tumor sizee
  ≤ 25 mm 223 (49.8) 40 (50.0) 132 (52.4) 51 (44.0) 0.32 (NS)
  > 25 mm 225 (50.2) 40 (50.0) 120 (47.6) 65 (56.0)  
ERα status
 Negative 118 (25.9) 9 (11.0) 67 (26.3) 42 (35.3) 0.00067
 Positive 338 (74.1) 73 (89.0) 188 (73.7) 77 (64.7)  
PR status
 Negative 194 (42.5) 31 (37.8) 103 (40.4) 60 (50.4) 0.12 (NS)
 Positive 262 (57.5) 51 (62.2) 152 (59.6) 59 (49.6)  
ERBB2 status
 Negative 357 (78.3) 71 (86.6) 200 (78.4) 86 (72.3) 0.052 (NS)
 Positive 99 (21.7) 11 (13.4) 55 (21.6) 33 (27.7)  
Molecular subtypes
 HR−ERBB2− 68 (14.9) 8 (9.8) 41 (16.1) 19 (16.0) 0.0015
 HR−ERBB2+ 45 (9.9) 1 (1.2) 22 (8.6) 22 (18.5)  
 HR+ERBB2− 289 (63.4) 63 (76.8) 159 (62.4) 67 (56.3)  
 HR+ERBB2+ 54 (11.8) 10 (12.2) 33 (12.9) 11 (9.2)  
PIK3CA mutation status
 Wild type 307 (67.3) 56 (68.3) 172 (67.5) 79 (66.4) 0.96 (NS)
 Mutated 149 (32.7) 26 (31.7) 83 (32.5) 40 (33.6)  
MKI67 mRNA expression
 Median 12.5 (0.80–117) 11.7 (1.74–117) 12.1 (0.80–94.5) 13.6 (2.1–58.5) 0.073 (NS)
  1. Abbreviations: ERα Estrogen receptor alpha, PR Progesterone receptor, ERBB2 Human epidermal growth factor receptor 2, HR Hormone receptor, PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, MKI67 Marker of proliferation Ki-67
  2. The bold values are statistically significant (P < 0.05)
  3. Numbers represent the part of the 456 patients in each condition (e.g., age, SBR histological grade) and in regard to the expression level group (Low ETV4/High ETV4-Low MMP13/High ETV4-High MMP13). For these three groups, percentages in brackets correspond to the proportion of patients in the group (82 for Low ETV4; 255 for High ETV4-Low MMP13; 119 for High ETV4-High MMP13)
  4. a χ2 test
  5. bScarff Bloom Richardson classification
  6. cInformation available for 447 patients
  7. dInformation available for 452 patients
  8. eInformation available for 448 patients